Balance Sheet

Accounts Payables Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Cost of Revenue Depreciation & Amortization (IS)EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Other Gross PP&E Adjustments Other Gross PP&E Adjustments Receivables - Net Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

BioNTech SE (BNTX) Receivables - Other (2018 - 2019)

BioNTech SE's Receivables - Other history spans 2 years, with the latest figure at $6.5 million for Q4 2019.

On a quarterly basis, Receivables - Other rose 142.11% to $6.5 million in Q4 2019 year-over-year; TTM through Dec 2019 was $6.5 million, a 142.11% increase, with the full-year FY2019 number at $6.5 million, up 133.93% from a year prior.
Receivables - Other hit $6.5 million in Q4 2019 for BioNTech SE, down from $8.8 million in the prior quarter.
Over the last five years, Receivables - Other for BNTX hit a ceiling of $8.8 million in Q3 2019 and a floor of $2.7 million in Q4 2018.